Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.

An ounce of prevention is worth….$7 billion, which is what Siemens AG , the number two player in diagnostic imaging, has offered to become the number three player in in vitro diagnostics. Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products Corp., to bring an immunodiagnostics business in-house, [See Deal] Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. [See Deal] Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche , and by its calculations, now plays a close third to Abbott Laboratories Inc. in the overall in vitro diagnostics (IVD) market, excluding the diabetes self testing segment, in which Siemens doesn't operate.

Not only do the IVD acquisitions represent a new source of recurring revenues from diagnostic test and reagents to a...

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.